Harvard Bioscience (HBIO) and The Competition Head-To-Head Review
Harvard Bioscience (NASDAQ: HBIO) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare Harvard Bioscience to related companies based on the strength of its analyst recommendations, dividends, earnings, valuation, risk, profitability and institutional ownership.
Volatility & Risk
Harvard Bioscience has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Harvard Bioscience’s rivals have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.
This table compares Harvard Bioscience and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Harvard Bioscience Competitors||-332.57%||-32.01%||-12.25%|
Institutional and Insider Ownership
61.0% of Harvard Bioscience shares are held by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 9.8% of Harvard Bioscience shares are held by insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Harvard Bioscience and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Harvard Bioscience||$100.79 million||$3.21 million||-28.08|
|Harvard Bioscience Competitors||$2.02 billion||$430.73 million||-66.96|
Harvard Bioscience’s rivals have higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations and price targets for Harvard Bioscience and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Harvard Bioscience Competitors||257||1822||3272||105||2.59|
Harvard Bioscience presently has a consensus price target of $5.75, indicating a potential upside of 57.53%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.58%. Given Harvard Bioscience’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Harvard Bioscience is more favorable than its rivals.
Harvard Bioscience beats its rivals on 8 of the 12 factors compared.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.